SMILE (PENTA 17)

SMILE (PENTA 17)

Strategy for Maintenance of HIV suppression with elvitegravir + darunavir/ritonavir in children (PENTA 17).

SMILE is a multicentre randomised study evaluating safety and antiviral effect of Elvitegravir administered with Darunavir/Ritonavir compared to standard of care among HIV-1 infected, virologically suppressed paediatric participants.

PENTA is sponsor of this study, with 300 children enrolled from about 30 sites from 10 countries. Results will be used to support regulatory submission for marketing of Elvitegravir combination therapy in this population.